Navigation Links
M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
Date:4/9/2010

MONTREAL, QUEBEC Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center may have found a way to more accurately predict treatment outcomes in young leukemia patients using information from a common and simple complete blood count test, also known as a CBC.

The results of a retrospective study were reported at the American Society of Pediatric Hematology Oncology's (ASPHO) annual meeting today. The study illustrated that the minimal residual disease (MRD) indicator and the absolute lymphocyte count (ALC) together enable physicians to better predict which patients with acute lymphocytic leukemia (ALL) will remain disease free and who will most likely relapse.

"Our ultimate goal is to use these prognostic tools in the future to guide treatments for our patients," said Patrick Zweidler-McKay, M.D. Ph.D., assistant professor at the Children's Cancer Hospital and first author on the study. "If we know that a patient is at high-risk for relapse from the beginning, then potentially we can adjust their treatment plan to a more aggressive therapy."

For several years, MRD has been the best prognostic tool used to predict whether a patient was at high-risk for relapse. At the 2007 ASPHO annual meeting, Zweidler-McKay reported that the ALC count can also be influential in predicting prognosis of pediatric leukemia patients. In this current study, results showed that ALC is as powerful as MRD, if not more, in independently predicting prognosis for children with ALL. By using ALC as a prognostic tool along with MRD, researchers were able to define a subgroup of patients who are more prone to relapse but were originally overlooked based on using MRD alone to predict prognosis.

The study was based on 171 pediatric ALL patients and showed that after a month of treatment, patients who were MRD positive with a low ALC had an event-free survival rate of 33 percent and an overall 5-year survival outcome of 41 percent. However, those who were MRD positive but with a high ALC had an event-free survival rate of 69 percent and overall 5-year survival of 92 percent. The most positive outcomes come from patients who are MRD negative and have high ALC. These patients have a 99 percent overall 5-year survival.

"MRD is an important tool for predicting prognosis," said Zweidler-McKay, "but it misses a subgroup of patients who, despite have low MRD, still are at high risk of relapse. Using the ALC information, we can define which patients fall into this category. Down the line, we hope this information will allow us to alter treatment to help prevent these patients from relapsing."


'/>"/>

Contact: Sara Farris
sfarris@mdanderson.org
713-792-9133
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. M. D. Anderson study questions true favorability of rare breast cancer type
2. David Anderson to discuss what model organisms can teach us about emotion
3. LodgeNet Healthcare Deploys Custom Education Solution for M. D. Anderson Cancer Center
4. M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
5. Costly tests may not help detect bladder cancer recurrence, M. D. Anderson study finds
6. Ultrasound measurement of fetal adrenal gland a better predictor of preterm birth
7. A better sign of blood vessel narrowing and early coronary artery disease
8. Sleep and Do Better
9. Genital Herpes Reactivation Better Understood
10. Couples who say we do better at resolving conflicts
11. Computers do better than humans at measuring some radiology images
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
(Date:12/8/2016)... ... , ... David J. Dykeman , Ginger Pigott , and ... at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg ... global Life Sciences & Medical Technology Group have been featured speakers at every DeviceTalks ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to ... convenient service for Texas, they are expanding their presence in Dallas. One of the ... that will bring new jobs to the Dallas and Forth Worth market. STAT takes ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... from offices headquartered in Hamilton County, is embarking on a charity drive with ... in finding new homes for orphaned or neglected senior dogs in the Cincinnati ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 Australia Glaucoma Surgery Devices ... new report, "Australia Glaucoma Surgery Devices Market Outlook ... Australia Glaucoma Surgery Devices market. The report provides ... units) and average prices (USD) within market segement ... provides company shares and distribution shares data for ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... to grow in 2017-2023. Various reasons for growth of ... population, higher incidences of chronic diseases, high recovery cost ... aid services. Medical lifting sling refers to an ... limited mobility. These slings connect to the lift and ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology: